References
- Bachu RD, Chowdhury P, Al-Saedi ZHF, Karla PK, Boddu SH. Ocular drug delivery barriers—role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics. 2018;10(1):1–28. doi:https://doi.org/10.3390/pharmaceutics10010028.
- Verma P, Gupta RN, Jha AK, Development PR. in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide. Drug Deliv. 2013;20(7):269–76. doi:https://doi.org/10.3109/10717544.2013.834417.
- Silva NC, Silva S, Sarmento B, Pintado M. Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis. Drug Deliv. 2015;22(7):885–93. doi:https://doi.org/10.3109/10717544.2013.858195.
- Kalam MA, Alshamsan A, Aljuffali IA, Sultana Y. Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination. Drug Deliv. 2016;23(3):896–907. doi:https://doi.org/10.3109/10717544.2014.920432.
- Resnikoff S, Pascolini D, Etyaale KI, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–51. doi:https://doi.org/10.1590/S0042-96862004001100009.
- Quigley HA, Broman AT. The number of people with glaucoma world-wide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–67. doi:https://doi.org/10.1136/bjo.2005.081224.
- Sacca SC, Pulliero A, Izzotti A. The dysfunction of the trabecular meshwork during glaucoma course. J Cell Physiol. 2015;230(3):510–25. doi:https://doi.org/10.1002/jcp.24826.
- Wentz SM, Kim NJ. Wang J Amireskandari A, Siesky B, Harris A. Novel Therapies for Open-angle Glaucoma F1000Prime Rep. 2014;6:102–10.
- Gautam N, Kesavan K. Development of microemulsions for ocular delivery. Ther Deliv. 2017;8(5):313–30. doi:https://doi.org/10.4155/tde-2016-0076.
- Fialho SL, Silva-Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Exp Ophthalmol. 2004;32(6):626–32. doi:https://doi.org/10.1111/j.1442-9071.2004.00914.x.
- Peng CC, Bengani LC, Jung HJ, Gupta C, Chauhan A. Emulsions and microemulsions for ocular drug delivery. J Drug Deliv Sci Technol. 2011;21(1):111–21. doi:https://doi.org/10.1016/S1773-2247(11)50010-3.
- Li Y, Song J, Tian N, Cai J, Huang M, Xing Q, Wang Y, Wu C, Hu H. Improving oral bioavailability of metformin hydrochloride using water-in-oil microemulsions and analysis of phase behavior after dilution. Int J Pharm. 2014;473(1–2):316–25. doi:https://doi.org/10.1016/j.ijpharm.2014.07.011.
- Wu Z, Alany RG, Tawfeek NW, Falconer J, Zhang W, Hassan IM, Rutland M, Svirskis D. A study of microemulsions as prolonged-release injectables through in-situ phase transition. J Control Release. 2014;174:188–94.
- Chan J, El Maghraby GMM, Craig JP, Alany RG. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm. 2007;328(1):65–71. doi:https://doi.org/10.1016/j.ijpharm.2006.10.004.
- Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2:337–46. doi:https://doi.org/10.2147/tcrm.2006.2.4.337.
- Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol. 2002;47(Suppl 1):S2–5. doi:https://doi.org/10.1016/S0039-6257(02)00291-6.
- Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv. 2007;14:507–15. doi:https://doi.org/10.1080/10717540701606426.
- Higuchi T. Mechanism of sustained action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–49. doi:https://doi.org/10.1002/jps.2600521210.
- Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35. doi:https://doi.org/10.1016/0378-5173(83)90064-9.
- Leng T, Miller JM, Bilbao KV, Palanker DV, Huie P, Blumenkranz MS. The chick chorioallantoic membrane as a model tissue for surgical retinal research and simulation. Retina. 2004;24(3):427–34. doi:https://doi.org/10.1097/00006982-200406000-00014.
- Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin- loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine. 2010;6(2):324–33. doi:https://doi.org/10.1016/j.nano.2009.10.004.
- Huang J, Peng T, Li Y, Zhan Z, Zeng Y, Huang Y, Pan X, Wu CY, Wu C. Ocular cubosome drug delivery system for timolol maleate: preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation. AAPS Pharmscitech. 2017;18(8):2919–26. doi:https://doi.org/10.1208/s12249-017-0763-8.
- Draize JH, Woodard G, Calvey HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;81:377–90.
- Park CG, Kim YK, Kim MJ, Kim MJ, Park M, Kim MH, Lee SH, Choi SY, Lee WS, Chung YJ, et al. Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug. J Control Release. 2015;220:180–88. doi:https://doi.org/10.1016/j.jconrel.2015.10.027.
- Bharti SK, Kesavan K. Phase-transition W/O microemulsions for ocular delivery: evaluation of antibacterial activity in the treatment of bacterial keratitis. Ocul Immunol Inflamm. 2016;25:1–12.
- Mudgil M, Pawar PK. Preparation and in vitro/ex vivo evaluation of moxifloxacin-loaded PLGA nanosuspensions for ophthalmic application. Sci Pharm. 2013;81(2):591–606. doi:https://doi.org/10.3797/scipharm.1204-16.
- Kesavan K, Kant S, Singh PN, Pandit JK. Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation. Curr Eye Res. 2013;38(3):342–52. doi:https://doi.org/10.3109/02713683.2012.745879.
- Spielmann H. Ocular irritation. In: Castle JV, Gomez MJ, editors. In Vitro methods in pharmaceutical research. San Diego (CA): Academic Press; 1997. p. 265–87.